brivudine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
uridine derivatives used as antiviral agents and as antineoplastics 397 69304-47-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • brivudine
  • brivudin
  • bromovinyldeoxyuridine
anti-herpes agent; (Z)-isomer much less active against herpes simplex virus type 1 & somewhat less active against herpes simplex virus type 2 than is the (E)-isomer; both isomers show similar activity against vaccinia virus; RN given refers to (E)-trans-isomer; structure
  • Molecular weight: 333.14
  • Formula: C11H13BrN2O5
  • CLOGP: -0.82
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 99.10
  • ALOGS: -1.66
  • ROTB: 3

Drug dosage:

DoseUnitRoute
0.13 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ
BA (Bioavailability) 30 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 46
kinase-selectivity-class AXL,CDK9,GRK2,IRAK1,MAP2K6,MAP3K14,PDK1,PRKDC,TEK 9
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.68

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pharyngeal inflammation 82.92 58.53 13 688 1047 90626699
Labelled drug-drug interaction medication error 73.65 58.53 18 683 14564 90613182
Oesophagitis 70.65 58.53 18 683 17231 90610515
Drug interaction 65.76 58.53 35 666 276418 90351328

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Labelled drug-drug interaction medication error 109.59 90.59 25 303 15557 42605450

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Labelled drug-drug interaction medication error 165.91 56.46 41 981 29261 110559016
Mucosal inflammation 110.10 56.46 39 983 96102 110492175
Drug interaction 82.08 56.46 53 969 500130 110088147
Pharyngeal inflammation 74.33 56.46 13 1009 1701 110586576
Pancytopenia 71.72 56.46 36 986 209577 110378700
Oesophagitis 71.27 56.46 21 1001 28694 110559583
Rash maculovesicular 59.37 56.46 7 1015 51 110588226

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AB15 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:68495 apoptosis inducer
CHEBI has role CHEBI:233442 chemosensitiser

Related Drugs by ATC class:

J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 11 drugs
acyclovircidofovirfamciclovirgancicloviridoxuridinemolnupiravirpenciclovirremdesivirvalaciclovirvalganciclovirvidarabine

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.2 acidic
pKa2 13.02 acidic
pKa3 13.7 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Thymidine kinase, cytosolic Kinase Ki 7 CHEMBL
Thymidine kinase Kinase Ki 6.62 CHEMBL
Thymidine kinase Kinase IC50 6.52 CHEMBL
Thymidine kinase Kinase IC50 4.49 CHEMBL

External reference:

IDSource
D07249 KEGG_DRUG
59161 RXNORM
C0163272 UMLSCUI
CHEBI:47278 CHEBI
CHEMBL31634 ChEMBL_ID
DB03312 DRUGBANK_ID
C020235 MESH_SUPPLEMENTAL_RECORD_UI
446727 PUBCHEM_CID
6267 INN_ID
2M3055079H UNII
698049003 SNOMEDCT_US
BVD PDB_CHEM_ID
006752 NDDF

Pharmaceutical products:

None